A Phase 2/3 interventional study of Propofol and Isoflurane in Acute Respiratory Distress Syndrome, Mechanical Ventilation Complication and Sedation Complication, sponsored by Guy's and St Thomas' NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Guy's and St Thomas' NHS Foundation Trust · Phase 2/3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom — 10 open to participants now, 13 under way, 3 of them phase 3. Respiratory Distress Syndrome · United Kingdom.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, this one is the 29th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 2/3, reaches primary completion later than 5 of the 12 other live ones, and was the 39th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →10 of the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 18–100
Aerogen Pharma Limited · Sites in United Kingdom, United States, Canada
Ages 1 hrs–24 hrs
BioAegis Therapeutics Inc. · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18+
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 34 wk–38 wk
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 17 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 8 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 90 across the 31 interventional studies, 132 across the 15 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 47 have an industry lead sponsor. The 10 most frequent:
Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.
Guy's and St Thomas' NHS Foundation Trust has 5 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Respiratory Distress Syndrome with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT06014138Phase 3Guy's and St Thomas' NHS Foundation TrustVolatile Sedation for Patients With the Acute Respiratory Distress Syndrome | 2027-07-31 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05388708University of MichiganARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) | 2027-06-30 |
| NCT07580781Guy's and St Thomas' NHS Foundation TrustFeasibility of Protocolised Analgosedation in ECMO | 2027-08-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate how different types of routine sedation may affect patient's breathing whilst on a ventilator in the Intensive Care Unit (ICU). There are different approaches to sedation which may have advantages and disadvantages. During the study patients will receive both intravenous and inhaled volatile sedation (similar to anaesthetic 'gases' used for general anaesthesia) and the drive to breath, breathing efforts and function of the lung will be assessed.
It is routine for patients to be sedated for their comfort and safety whilst on a ventilator in the Intensive Care Unit (ICU). Conventionally sedatives are given intravenously, however inhaled volatile sedation is becoming more popular. Inhaled sedation has recently been approved by the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK).
Whilst being on a ventilator can be life-saving, it can cause potential problems. It is important that the patient interacts well with the ventilator and that their own breathing efforts are well regulated. There is evidence that inhaled sedation can specifically help the lungs when patients have the Acute Respiratory Distress Syndrome (ARDS) and in particular, inhaled sedation does not appear to suppress patient's own breathing as much as conventional sedation. Greater spontaneous breathing by the patient is usually positive but needs to be carefully understood to ensure it is not excessive or damaging to the patient's already injured lungs.
This study of 20 patients is designed to carefully measure the impact of inhaled sedation on the patient's breathing and lung function, in comparison to intravenous sedation. Measurements will be taken whilst on intravenous sedation before the patient is switched to an equivalent level of inhaled sedation for six hours, when the measurements will be repeated. Finally, the patient will go back to their original intravenous sedation and the measurements taken again. This is called a 'cross-over' study and is a good way to evaluate the effect of the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conventional intravenous sedation (e.g. propofol) with short acting opioid, titrated to a clinically prescribed sedation score. Period of observation will be 2 hours pre-cross over and 2 hours post cross over.
Drug: Propofol
Inhaled volatile sedation (Isoflurane) delivered via the AnaConDa device for a 6 hour period (2 hours washout of intravenous sedation / wash-in of volatile to achieve stable baseline, followed by 4 hours of observations at steady state) titrated to an equivalent sedation score. During this period opioid infusion should be maintained at baseline level unless clinical indication for titration of dose.
Drug: Isoflurane
Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
Respiratory drive (P0.1)
Negative pressure in the first 100milliseconds of inspiration (P0.1) - Physiological parameter
Time frame: 8 hours
Respiratory effort (Pmus)
End expiratory occlusion pressure (Pmus) - Physiological parameter
Time frame: 8 hours
Respiratory effort (PMI)
Pressure Muscle Index (PMI) - Physiological parameter
Time frame: 8 hours
Respiratory effort (Oesophageal pressure swings)
Oesophageal pressure swings - Physiological parameter
Time frame: 8 hours
Gas exchange (PaO2:FiO2 ratio)
Ratio of arterial partial pressure of oxygen to fractional inspired concentration of oxygen (PaO2:FiO2) - Physiological parameter
Time frame: 8 hours
Gas exchange (pulmonary shunt fraction (Qs/Qt))
Pulmonary shunt fraction (Qs/Qt) - Physiological parameter
Time frame: 8 hours
Gas exchange ( ratio of ventilatory 'dead space' to tidal volume (Vd/Vt))
ratio of ventilatory 'dead space' to tidal volume (Vd/Vt) - Physiological parameter
Time frame: 8 hours
Gas exchange (volume of carbon dioxide breathed out (VCO2))
volume of carbon dioxide breathed out (VCO2) - Physiological parameter
Time frame: 8 hours
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isoflurane
Respiratory Distress Syndrome →
Guy's and St Thomas' NHS Foundation Trust →